Literature DB >> 16835385

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells.

Jonathan M Irish1, Debra K Czerwinski, Garry P Nolan, Ronald Levy.   

Abstract

The B-cell receptor (BCR) transmits life and death signals throughout B-cell development, and altered BCR signaling may be required for survival of B-lymphoma cells. We used single-cell signaling profiles to compare follicular lymphoma (FL) B cells and nonmalignant host B cells within individual patient biopsies and identified BCR-mediated signaling events specific to lymphoma B cells. Expression of CD20, Bcl-2, and BCR light chain isotype (kappa or lambda) distinguished FL tumor B-cell and nontumor host B-cell subsets within FL patient biopsies. BCR-mediated signaling via phosphorylation of Btk, Syk, Erk1/2, and p38 occurred more rapidly in tumor B cells from FL samples than in infiltrating nontumor B cells, achieved greater levels of per-cell signaling, and sustained this level of signaling for hours longer than nontumor B cells. The timing and magnitude of BCR-mediated signaling in nontumor B cells within an FL sample instead resembled that observed in mature B cells from the peripheral blood of healthy subjects. BCR signaling pathways that are potentiated specifically in lymphoma cells should provide new targets for therapeutic attention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835385      PMCID: PMC1895530          DOI: 10.1182/blood-2006-02-003921

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

Authors:  K P Lam; R Kühn; K Rajewsky
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

2.  The strength of receptor signaling is centrally controlled through a cooperative loop between Ca2+ and an oxidant signal.

Authors:  Dinesh Kumar Singh; Dhiraj Kumar; Zaved Siddiqui; Sandip Kumar Basu; Vikas Kumar; Kanury V S Rao
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

Review 3.  Killing time for cancer cells.

Authors:  Shoshana Klein; Frank McCormick; Alexander Levitzki
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

4.  Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

Authors:  T A Davis; D G Maloney; D K Czerwinski; T M Liles; R Levy
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

Review 5.  Initiation and processing of signals from the B cell antigen receptor.

Authors:  M Reth; J Wienands
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Authors:  Aleksandar Petlickovski; Luca Laurenti; Xiaoping Li; Sara Marietti; Patrizia Chiusolo; Simona Sica; Giuseppe Leone; Dimitar G Efremov
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

Review 7.  Mechanisms of B-cell lymphoma pathogenesis.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

8.  Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein.

Authors:  W M Vuist; R Levy; D G Maloney
Journal:  Blood       Date:  1994-02-15       Impact factor: 22.113

9.  A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.

Authors:  M Takata; T Kurosaki
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

10.  Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling.

Authors:  T Kurosaki; S A Johnson; L Pao; K Sada; H Yamamura; J C Cambier
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  63 in total

Review 1.  The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.

Authors:  Vaishalee P Kenkre; Brad S Kahl
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

Review 2.  Single-cell mass cytometry for analysis of immune system functional states.

Authors:  Zach B Bjornson; Garry P Nolan; Wendy J Fantl
Journal:  Curr Opin Immunol       Date:  2013-08-31       Impact factor: 7.486

3.  The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.

Authors:  S Kheirallah; S Fruchon; L Ysebaert; A Blanc; F Capilla; A Marrot; T Alsaati; F X Frenois; K A Benhadji; J J Fournié; G Laurent; C Bezombes
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.

Authors:  Rada Amin; Frédéric Mourcin; Fabrice Uhel; Céline Pangault; Philippe Ruminy; Loic Dupré; Marion Guirriec; Tony Marchand; Thierry Fest; Thierry Lamy; Karin Tarte
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

5.  Cutting Edge: Redox Signaling Hypersensitivity Distinguishes Human Germinal Center B Cells.

Authors:  Kanutte Huse; Jonathan M Irish; Hannah G Polikowsky; Cara E Wogsland; Kirsten E Diggins
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422

6.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Authors:  Stephen E Spurgeon; Greg Coffey; Luke B Fletcher; Russell Burke; Jeffrey W Tyner; Brian J Druker; Andreas Betz; Francis DeGuzman; Yvonne Pak; Dale Baker; Anjali Pandey; Stanley J Hollenbach; Uma Sinha; Marc M Loriaux
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

8.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

9.  Characterization of patient specific signaling via augmentation of Bayesian networks with disease and patient state nodes.

Authors:  Karen Sachs; Andrew J Gentles; Ryan Youland; Solomon Itani; Jonathan Irish; Garry P Nolan; Sylvia K Plevritis
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

10.  Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.

Authors:  Soung-Chul Cha; Hong Qin; Shibichakravarthy Kannan; Seema Rawal; Leticia S Watkins; Flavio E Baio; Weiguo Wu; Juliana Ong; Jinsong Wei; Benjamin Kwak; Sang Kim; Michael S Popescu; Daniel S Paick; Kunhwa Kim; Amber Luong; Richard E Davis; Harry W Schroeder; Larry W Kwak; Sattva S Neelapu
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.